Brind.

Cytosorbents is conducting research and commercialization in the US and Germany.

1 report, 0 independent Updated Jul 2

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Who's involved

What this event is mainly about

Cytosorbents

Keep exploring

The entities involved

Cytosorbents
company
- Cytosorbents regained the minimum bid price requirement of $1.00 per share on Nasdaq and is advancing its DrugSorb-ATR product toward FDA regulatory approval.Wed 12:13

Related events

Cytosorbents held an investor conference in New York City.Sep 10

Coverage

Newest first; wire copies grouped

Jul 2Unknown outlet